Literature DB >> 24852894

Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles.

Sabine May1, Birte Jensen, Claudius Weiler, Markus Wolkenhauer, Marc Schneider, Claus-Michael Lehr.   

Abstract

PURPOSE: The aim of this study was to investigate influencing factors on the dissolution test for powders for pulmonary delivery with USP apparatus 2 (paddle apparatus).
METHODS: We investigated the influence of dose collection method, membrane holder type and the presence of surfactants on the dissolution process. Furthermore, we modeled the in vitro dissolution process to identify influencing factors on the dissolution process of inhaled formulations based on the Nernst-Brunner equation.
RESULTS: A homogenous distribution of the powder was required to eliminate mass dependent dissolution profiles. This was also found by modeling the dissolution process under ideal conditions. Additionally, it could be shown that influence on the diffusion pathway depends on the solubility of the substance.
CONCLUSION: We demonstrated that the use of 0.02% DPPC in the dissolution media results in the most discriminating and reproducible dissolution profiles. In the model section we demonstrated that the dissolution process depends strongly on saturation solubility and particle size. Under defined assumptions we were able show that the model is predicting the experimental dissolution profiles.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24852894     DOI: 10.1007/s11095-014-1413-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  General solution for diffusion-controlled dissolution of spherical particles. 1. Theory.

Authors:  J Wang; D R Flanagan
Journal:  J Pharm Sci       Date:  1999-07       Impact factor: 3.534

2.  Dissolution techniques for in vitro testing of dry powders for inhalation.

Authors:  Sabine May; Birte Jensen; Markus Wolkenhauer; Marc Schneider; Claus Michael Lehr
Journal:  Pharm Res       Date:  2012-04-20       Impact factor: 4.200

3.  Tailor-made biofunctionalized nanoparticles using layer-by-layer technology.

Authors:  Hagar I Labouta; Marc Schneider
Journal:  Int J Pharm       Date:  2010-05-21       Impact factor: 5.875

4.  A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.

Authors:  Aristides Dokoumetzidis; Panos Macheras
Journal:  Int J Pharm       Date:  2006-07-15       Impact factor: 5.875

5.  Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development.

Authors:  Kiyohiko Sugano
Journal:  Int J Pharm       Date:  2008-07-15       Impact factor: 5.875

6.  Development of a standardized dissolution test method for inhaled pharmaceutical formulations.

Authors:  Yoen-Ju Son; Jason T McConville
Journal:  Int J Pharm       Date:  2009-08-07       Impact factor: 5.875

7.  A novel method for assessing dissolution of aerosol inhaler products.

Authors:  Neal M Davies; Majid R Feddah
Journal:  Int J Pharm       Date:  2003-04-14       Impact factor: 5.875

8.  Dissolution modeling: factors affecting the dissolution rates of polydisperse powders.

Authors:  A T Lu; M E Frisella; K C Johnson
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products.

Authors:  Deepika Arora; Kumar A Shah; Matthew S Halquist; Masahiro Sakagami
Journal:  Pharm Res       Date:  2010-03-13       Impact factor: 4.200

10.  Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols.

Authors:  Rania O Salama; Daniela Traini; Hak-Kim Chan; Paul M Young
Journal:  Eur J Pharm Biopharm       Date:  2008-04-22       Impact factor: 5.571

View more
  7 in total

1.  Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.

Authors:  Sharvari Bhagwat; Uta Schilling; Mong-Jen Chen; Xiangyin Wei; Renishkumar Delvadia; Mohammad Absar; Bhawana Saluja; Günther Hochhaus
Journal:  Pharm Res       Date:  2017-08-10       Impact factor: 4.200

2.  Synthesis and evaluation of mesoporous carbon/lipid bilayer nanocomposites for improved oral delivery of the poorly water-soluble drug, nimodipine.

Authors:  Yanzhuo Zhang; Qinfu Zhao; Wufu Zhu; Lihua Zhang; Jin Han; Qisi Lin; Fengwei Ai
Journal:  Pharm Res       Date:  2015-01-22       Impact factor: 4.200

3.  Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening.

Authors:  Eleonore Fröhlich
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Characterization of Membrane-Type Dissolution Profiles of Clinically Available Orally Inhaled Products Using a Weibull Fit and a Mechanistic Model.

Authors:  Irès van der Zwaan; Frans Franek; Rebecca Fransson; Ulrika Tehler; Göran Frenning
Journal:  Mol Pharm       Date:  2022-08-08       Impact factor: 5.364

5.  A Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition.

Authors:  Abhinav Kumar; Wachirun Terakosolphan; Mireille Hassoun; Kalliopi-Kelli Vandera; Astrid Novicky; Richard Harvey; Paul G Royall; Elif Melis Bicer; Jonny Eriksson; Katarina Edwards; Dirk Valkenborg; Inge Nelissen; Dave Hassall; Ian S Mudway; Ben Forbes
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

6.  Human airway construct model is suitable for studying transcriptome changes associated with indoor air particulate matter toxicity.

Authors:  Maria-Elisa Nordberg; Martin Täubel; Pasi I Jalava; Kelly BéruBé; Arja Tervahauta; Anne Hyvärinen; Kati Huttunen
Journal:  Indoor Air       Date:  2020-01-23       Impact factor: 5.770

7.  Model for the Analysis of Membrane-Type Dissolution Tests for Inhaled Drugs.

Authors:  Göran Frenning; Irès van der Zwaan; Frans Franek; Rebecca Fransson; Ulrika Tehler
Journal:  Mol Pharm       Date:  2020-06-15       Impact factor: 4.939

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.